Etigilimab

DB18854InvestigationalProtein Based Therapies

Etigilimab is under investigation in clinical trial NCT04761198 (A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors.).

Mechanism: Pharmacologically active on T-cell immunoreceptor with Ig and ITIM domains
Curator reviewed
Also known as: Immunoglobulin g1, anti-(human receptor tigit(t-cell immunoreceptor with ig and itim domains)) (humanized mouse monoclonal omp-313m32 .gamma.1-chain), disulfide with humanized mouse monoclonal omp-313m32 .kappa.-chain, dimer

Resolves to

Compound

UNIIFC1ZF28VITCAS2044984-83-8

Targets

Q495A1TIGIT

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Etigilimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account